Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fuzhengzaohua is a Traditional Chinese Medicine (TCM) formulation primarily utilized in clinical practice to treat leukopenia and bone marrow suppression, particularly as a supportive therapy for patients undergoing chemotherapy or radiotherapy. The formulation is based on the TCM principle of 'strengthening the body's resistance and promoting blood cell transformation' (Fuzheng Zaohua). It typically consists of a combination of herbal ingredients, including *Astragalus membranaceus* (Huangqi), *Codonopsis pilosula* (Dangshen), *Rehmannia glutinosa* (Shudihuang), and *Spatholobus suberectus* (Jixueteng). The drug works by stimulating hematopoietic functions within the bone marrow, specifically by inducing the production of endogenous growth factors and modulating the immune microenvironment. It is frequently administered as a hospital-prepared oral liquid or decoction in oncology departments across China to mitigate the myelosuppressive side effects of anti-cancer treatments.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Fuzhengzaohua.